Special Issue

Transgenic Mice in Human Diseases: Insights from Genetic Research

Message from the Guest Editor

Transgenic mice, genetically engineered to carry specific human genes, have become invaluable tools in biomedical research. By introducing human genes into the mouse genome, scientists can create models of human diseases, allowing for a deeper understanding of disease mechanisms and the testing of potential therapies.

These models are essential for studying a wide range of human diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, and metabolic disorders.

Moreover, transgenic mice offer a controlled environment for studying gene function and interaction. By manipulating specific genes, scientists can uncover the underlying genetic basis of complex diseases and identify potential therapeutic targets. This knowledge can lead to the development of more effective and targeted treatments for human diseases.

In conclusion, transgenic mice have revolutionized biomedical research by providing a powerful platform for studying human diseases. Their versatility and precision make them indispensable tools in the quest for new therapies and improved patient outcomes.

Guest Editor

Dr. Andrei Golovko

Texas A&M Institute for Genomic Medicine, College Station, TX 77845, USA

Deadline for manuscript submissions

closed (20 June 2025)

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/si/225907

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/journal/genes

MDPI

About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))